by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP
Symptoms of advanced myeloproliferative neoplasms (MPN) negatively impact quality of life and include fatigue, night sweats, itching, bone/muscle p......READ MORE
by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP
Achieving durable cytoreduction and adequate symptom relief in patients with polycythemia vera (PV) is a primary treatment challenge. Individual re......READ MORE
by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP
Risk stratification provides an important basis for therapeutic decision making in patients with myeloproliferative neoplasms (MPN). Traditional ri......READ MORE
by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP
Cytoreduction with hydroxyurea is ineffective or intolerable in up to 25% of patients with polycythemia vera (PV). Second-line options for cytoredu......READ MORE
